Skip to content

The elucidation of placental origins of pregnancy disorders.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000028772
Enrollment
80
Registered
2017-08-22
Start date
2016-09-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fetal growth restriction and hypertensive pregnancy disorders

Interventions

None listed

Sponsors

Mie university hospital, Department of Obstetrics and Gynecology
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Age>=20 2. Gestational age between 20 + 0 and 33 + 6 weeks in pregnant women. 3. The expected date of confinement is determined using the criteria of the guidelines for obstetrical practice in Japan (2014) in pregnant women. 4. Singleton pregnancy. 5. Written informed consent.

Exclusion criteria

Exclusion criteria: Attending physician decides to entry inappropriate.

Design outcomes

Primary

MeasureTime frame
Comparison of expression of maternal serum protein and cell-free RNA between pregnant women complicated with and without placental origin of pregnancy disorders.

Secondary

MeasureTime frame
1. Pathological findings of the placenta. 2. Expression of maternal serum protein and cell-free RNA in the maternal blood. 3. Expression of protein and gene levels in the placenta. 4. Relationship between maternal blood concentration of tadalafil and urine concentration of cGMP. 5. Concentration of tadalafil in the cord blood. 6. Concentration of cGMP in the cord blood. 7. Relationship between maternal blood concentration of tadalafil and perinatal factors. 8. Relationship between concentration of tadalafil in the cord blood and perinatal factors.

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026